KDNY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KDNY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Chinook Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $4.27 Mil. Chinook Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $29.72 Mil. Chinook Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2023 was $488.81 Mil. Chinook Therapeutics's debt to asset for the quarter that ended in Jun. 2023 was 0.07.
The historical data trend for Chinook Therapeutics's Debt-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chinook Therapeutics Annual Data | |||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | |||||
Debt-to-Asset | 0.13 | 0.10 | 0.08 | 0.07 |
Chinook Therapeutics Quarterly Data | ||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
Debt-to-Asset | Get a 7-Day Free Trial | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 |
For the Biotechnology subindustry, Chinook Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Chinook Therapeutics's Debt-to-Asset distribution charts can be found below:
* The bar in red indicates where Chinook Therapeutics's Debt-to-Asset falls into.
Debt to Asset measures the financial leverage a company has.
Chinook Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as
Debt-to-Asset | = | Total Debt | / | Total Assets | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Assets | |
= | (4.948 | + | 34.494) | / | 574.084 | |
= | 0.07 |
Chinook Therapeutics's Debt-to-Asset for the quarter that ended in Jun. 2023 is calculated as
Debt-to-Asset | = | Total Debt | / | Total Assets | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Assets | |
= | (4.268 | + | 29.717) | / | 488.811 | |
= | 0.07 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chinook Therapeutics (NAS:KDNY) Debt-to-Asset Explanation
In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.
Thank you for viewing the detailed overview of Chinook Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Andrew James King | officer: Head of Renal Discovery | C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102 |
William Mariner Greenman | director | C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD CA 94520 |
Eric Dobmeier | director, officer: President, CEO | C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021 |
Davis Jerel | director, 10 percent owner | ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
Robert Azelby | director | 307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109 |
Mahesh Krishnan | director | 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104 |
Andrew Oxtoby | officer: Chief Commercial Officer | 8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005 |
Tom Frohlich | officer: Chief Business Officer | C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102 |
Eric Bjerkholt | officer: Chief Financial Officer | 132 PURDURE AVENUE, KENGSINGTON CA 94708 |
Dolca Thomas | director | C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Srinivas Akkaraju | director | 565 EVERETT AVENUE, PALO ALTO CA 94301 |
Alan Glicklich | officer: Chief Medical Officer | C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102 |
Versant Voyageurs I, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
Versant Voyageurs I Parallel, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
Versant Venture Capital Vii, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
From GuruFocus
By PRNewswire • 06-27-2023
By GlobeNewswire GlobeNewswire • 06-17-2023
By sperokesalga sperokesalga • 06-17-2023
By PRNewswire • 07-12-2023
By Business Wire • 07-21-2023
By sperokesalga sperokesalga • 06-14-2023
By Marketwired • 06-22-2023
By Marketwired • 07-26-2023
By PRNewswire PRNewswire • 06-20-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.